According to a new study, the prevalence of keratosis pilaris is low in patients with atopic dermatitis.

Tildrakizumab treatment for psoriasis showed a significant improvement when used for difficult-to-treat areas.

Depressive symptoms are closely linked to AD severity and can fluctuate alongside AD severity.

Dupilumab shows safety and efficacy for up to four years in treatment of moderate-to-severe atopic dermatitis in adults.

Patients with psoriasis are at an increased risk of developing alopecia areata.

Microbotox is effective in treating mild-to-moderate acne vulgaris and erythematotelangiectatic rosacea, according to a new study.

Patients with AD are more likely to achieve mild disease severity when treated with dupilumab and adjuvant tacrolimus vs dupilumab alone.

Registration is open for the inaugural Atopic Dermatitis Summit. The virtual even will be held on Saturday, April 23, 2022 at 10am EDT.